Court dismisses Verus suit against AZ

AstraZeneca has won dismissal of a lawsuit in which it was accused of backing out of a deal with Verus Pharmaceuticals to develop a children's asthma drug and instead aligning with competitor Map Pharmaceuticals. Verus had been seeking at least $280 million in compensatory damages and $1 billion in punitive damages. Verus claimed that once AstraZeneca entered a deal with Map, it sought to kill any competition by destroying Verus's ability to develop the drug on its own. Article | Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.